Edition:
United Kingdom

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

7.26USD
14 Nov 2018
Change (% chg)

$-0.32 (-4.22%)
Prev Close
$7.58
Open
$7.68
Day's High
$7.72
Day's Low
$7.21
Volume
206,924
Avg. Vol
137,688
52-wk High
$21.35
52-wk Low
$7.21

Latest Key Developments (Source: Significant Developments)

Epizyme Reports Q3 EPS of $0.54 Per Share
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Epizyme Inc ::EPIZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND TAZEMETOSTAT PROGRESS.Q3 LOSS PER SHARE $0.54.Q3 EARNINGS PER SHARE VIEW $-0.61 -- THOMSON REUTERS I/B/E/S.RESEARCH AND DEVELOPMENT EXPENSES WERE $27.0 MILLION FOR Q3 OF 2018, WHICH COMPARES TO $28.7 MILLION FOR Q3 OF 2017.EXPECTS EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND ITS PLANNED OPERATIONS INTO Q1 OF 2020.ENROLLMENT IN PHASE 2 COHORT OF FOLLICULAR LYMPHOMA PATIENTS WITH EZH2 ACTIVATING MUTATIONS ON TRACK TO BE COMPLETED BY YEAR END.RECENT FINANCING EXTENDS OPERATING RUNWAY INTO Q1 OF 2020.EPIZYME - UPDATED EFFICACY & SAFETY DATA FOR TAZEMETOSTAT IN EPITHELIOID SARCOMA SUPPORT CO'S PLANNED SUBMISSION OF NEW DRUG APPLICATION IN H1 OF 2019.  Full Article

Epizyme Says Positive Data On Tazemetostat In Epithelioid Sarcoma From Phase 2 Trial Cohort At ESMO
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Epizyme Inc ::EPIZYME REPORTS POSITIVE DATA ON TAZEMETOSTAT IN EPITHELIOID SARCOMA FROM ITS PHASE 2 TRIAL COHORT AT ESMO.EPIZYME - UPDATED EFFICACY, SAFETY DATA SUPPORT CO'S PLANNED SUBMISSION OF A NEW DRUG APPLICATION FOR TAZEMETOSTAT FOR EPITHELIOID SARCOMA IN H1 2019.  Full Article

Epizyme Announces Pricing Of Public Offering Of Common Stock
Wednesday, 3 Oct 2018 

Oct 2 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.33 MILLION COMMON SHARES PRICED AT $9.00PER SHARE.  Full Article

Epizyme Announces Proposed Public Offering Of Common Stock
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EPIZYME - TO USE PROCEEDS FROM OFFERING, TO FUND GLOBAL DEVELOPMENT COMMERCIALIZATION COSTS OF TAZEMETOSTAT OUTSIDE OF JAPAN.  Full Article

Epizyme Says U.S. FDA Lifted Partial Clinical Hold On Tazemetostat Clinical Program
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES THE U.S. FOOD AND DRUG ADMINISTRATION LIFTS PARTIAL CLINICAL HOLD ON TAZEMETOSTAT CLINICAL PROGRAM.EPIZYME INC - CO IS NOW IN PROCESS OF REOPENING ENROLLMENT IN ALL OF ITS COMPANY-SPONSORED TRIALS IN U.S..EPIZYME INC - WILL NOW ENGAGE WITH REGULATORS IN FRANCE AND GERMANY TO RESOLVE PARTIAL CLINICAL HOLDS AND RESUME ENROLLMENT IN THOSE COUNTRIES.  Full Article

Epizyme Reports Q2 Loss Per Share $0.42
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Epizyme Inc ::EPIZYME REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q2 LOSS PER SHARE $0.42.Q2 REVENUE $12 MILLION VERSUS $10 MILLION.Q2 REVENUE VIEW $538,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S.  Full Article

Epizyme Provides Update Regarding Tazemetostat Clinical Program
Monday, 23 Apr 2018 

April 23 (Reuters) - Epizyme Inc ::EPIZYME PROVIDES UPDATE REGARDING TAZEMETOSTAT CLINICAL PROGRAM.U.S.-BASED ENROLLMENT OF NEW PATIENTS INTO TAZEMETOSTAT CLINICAL TRIALS IS TEMPORARILY ON HOLD.PATIENTS ON STUDY WHO HAVE NOT EXPERIENCED DISEASE PROGRESSION MAY CONTINUE TO RECEIVE TAZEMETOSTAT.EPIZYME HAS BEGUN DEVELOPING MODIFICATIONS TO ADDRESS PARTIAL CLINICAL HOLD.CO WILL NEED TO CONFIRM ALIGNMENT WITH FDA IN ORDER TO RESUME U.S. ENROLLMENT.EPIZYME -U.S. FDA ISSUED PARTIAL CLINICAL HOLD AFFECTING NEW ENROLLMENT OF PATIENTS WITH GENETICALLY DEFINED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES.PARTIAL CLINICAL HOLD WAS INITIATED FOLLOWING A SAFETY REPORT, SUBMITTED BY EPIZYME TO FDA AND OTHER REGULATORY AUTHORITIES.EPIZYME-REPORT WAS REGARDING A PATIENT WITH ADVANCED POORLY DIFFERENTIATED CHORDOMA IN PHASE 1 PEDIATRIC STUDY WHO DEVELOPED SECONDARY T-CELL LYMPHOMA.PATIENT WHO DEVELOPED A SECONDARY T-CELL LYMPHOMA HAS NOW DISCONTINUED TAZEMETOSTAT AND IS BEING TREATED FOR T-CELL LYMPHOMA.  Full Article

Epizyme says ‍no revenue recognized in Q3 of 2017 compared to $6.6 mln for Q3 of 2016​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Epizyme Inc :Epizyme reports third quarter 2017 operating results and company updates.Epizyme Inc - ‍no revenue recognized in q3 of 2017, compared to $6.6 million for q3 of 2016​.Epizyme Inc - ‍research and development (research and development) expenses were $28.7 million for q3 of 2017, compared to $23.9 million​.Epizyme Inc - ‍existing cash, cash equivalents and marketable securities as of sept 30 will be sufficient to fund planned operations into at least q3 2019​.  Full Article

CORRECTED-BRIEF-Epizyme Reports Q3 Loss of $0.54 Per Share

* EPIZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND TAZEMETOSTAT PROGRESS